Skip to main content

Table 2 Multivariate Cox proportional hazard analysis with overall survival as endpoint

From: Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer

  Patients, n Multivariate HR (95% CI) P value
Age
 < 60 70 1.00 (ref)  
 60–74 176 1.70 (0.91–3.18) 0.099
 ≥ 75 173 3.42 (1.84–6.34) < 0.001
Stage
 I 78 1.00 (ref)  
 II 168 1.24 (0.66–2.34) 0.498
 III 117 2.32 (1.24–4.34) 0.009
 IV 56 11.10 (5.91–20.85) < 0.001
ZNF331 methylation
ZNF331 unmeth 121 1.00 (ref)  
ZNF331 meth 298 1.44 (0.97–2.14) 0.069
  1. Variables not selected by the backward likelihood method to be included in the final model: series, gender, CIMP-, MSI-, and BRAF mutation status
  2. Meth methylated, unmeth unmethylated